IL‐10 receptor is a therapeutic target in DLBCL171 and an IL‐10 receptor‐neutralizing antibody prevented STAT3 activation (phosphorylation) and induction of PD‐L1 protein expression.170 Levels of activated STAT3 also correlate with PD‐L1 protein expression in primary DLBCL.170 Therefore, BTK inhibition, NFAT targeting, or IL‐10 blocking could potentially be used to improve the efficacy of T cell‐directed therapies. Here, BTK is linked to diffuse large B-cell lymphoma.